Table 3.
Drugs and targets for the reverse cell identity
| Therapeutic intervention (single/in combination | Clinical status of drug | Clinical outcome | Indications | Ref |
|---|---|---|---|---|
| Enhancer of zeste homolog 2 (EZH2) | ||||
| GSK2816126 | Phase I | Due to insufficient clinical activity, the trial was discontinued | Solid tumors and DLBCL | NCT02082977 |
| Tazemetostat | Phase I/II | A good safety record and antitumor activity | Progressive solid tumors and B cell lymphoma | NCT01897571 [247] |
| PF-06821497 | Phase I | Recruiting | Castration-resistant prostate cancer (CRPC) | NCT03460977 [248] |
| Dual HDAC and HMGR inhibitor | ||||
| JMF3086 | Preclinical | Restores EGFR-TKI sensitivity | Non-small cell lung cancer | [249] |